You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Opdivo plus Yervoy combo approved in EU for first-line lung cancer

Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) has received approval from the European Commission for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC).